

British Academy Conference

Resolving Global Vaccine Inequity: Innovation, Capabilities & Governance



SOAS University of London
11-12 April 2024



The development of Covid-19 vaccines within a year of the emergence of SARS-CoV-2 was an unprecedented triumph of scientific research that saved millions of lives. In contrast, the lack of global coordination to manage intellectual property, technology transfer, production, financing, and distribution of vaccines led to excess deaths and losses in economic output. There is urgent need for greater understanding of how to organise society on a global scale to speed up both the transfer of knowledge and technology, and the production and distribution of vaccines. This conference brings together academics, practitioners, and policymakers to explore the factors that supported or inhibited vaccine distribution and technology transfer. Our purpose is to learn the lessons of the SARS-CoV-2 pandemic so that national and international society will be better organised to respond to future pandemics and public health crises.

Conference Registration

2-day rate: £20 (£10 for students) - includes lunch and refreshments

1-day rate: £12 (£6 for students) - includes lunch and refreshments



Conference Organiser

Professor Christine Oughton, SOAS University of London

Conference Programme Committee

Professor William Lazonick, Professor Christine Oughton and Dr. Öner Tulum






SOAS
University of London



CIFAR
CANADIAN
INSTITUTE
FOR
ADVANCED
RESEARCH



Resolving Global Vaccine Inequity: Innovation, Capabilities and Governance
SOAS University of London and The British Academy
11-12 April 2024

Conference Programme and Themes

The scientific development of vaccines to protect against Covid-19 in less than a year was a remarkable achievement. The speed of development rested on scientific collaboration, funding and knowledge sharing between key players - scientists, government, and business. From the team of Chinese researchers that sequenced and shared the genetic code of SARS-CoV-2, to international trials spanning Brazil, the UK, South Africa, and Kenya, to government funding of R&D and the fast-tracking of approvals, there was an impressive collective effort. In contrast, the manufacturing roll-out and distribution of the vaccines was problematic, characterised by bottlenecks, hoarding and vaccine inequity.

While the first vaccines were approved for use in December 2020, global vaccine diffusion was slow and uneven. Initially, COVAX in partnership with WHO and GAVI, set a target of 20% coverage by the end of 2021, that was subsequently increased to 40% with an additional target of 70% of the adult population in all countries by mid-2022. However, even the most modest targets for vaccine rollout were not met, with consequent negative effects on public health and economic output. It has been estimated that had the COVAX 20% and 40% targets been achieved, around 680,000 deaths would have been avoided in low- and middle-income countries (Watson *et al*, 2022, p. 1298).

The success of science was not matched by the same degree of success on the socio-economic side, but the science and social science of vaccines and public health are intrinsically linked. Equitable distribution of vaccines is important not just on humanitarian grounds, but also on grounds of vaccine efficacy. Without uniformly high levels of coverage, the virus was free to mutate in the unvaccinated population, thus undermining vaccine effectiveness and prolonging the pandemic.

This conference is focused on improving our socio-economic understanding of the pandemic so that science and social science can develop solutions in tandem. We need greater understanding of why, in the presence of scientifically proven solutions to the Covid-19 pandemic, it remained difficult to implement them in a timely manner. Understanding the process of scientific knowledge transfer and adaptation of vaccines for local use is crucial.

This conference brings together scientists, social scientists, practitioners, and policy makers to generate new, interdisciplinary, understanding to meet the global challenges that were posed by Covid-19 and that future pandemics will have to confront. The conference will explore the scientific, organisational, management, economic and governance factors that supported or inhibited knowledge and technology transfer as well as production and equitable distribution of Covid-19 vaccines. Our purpose is to enable us to learn the lessons of the SARS-CoV-2 pandemic so that, within and among nations, society will be better organised to respond to future pandemics and public health crises.

The conference is organised around 4 interrelated themes:

1. **R&D, Vaccine Invention, and Innovation**
2. **Vaccine Nationalism, Vaccine Inequity, Production and IPR**
3. **Building Capabilities and Strengthening Innovation Systems, Technology Transfer and Manufacturing in Low and Middle-Income Countries**
4. **Strengthening Global Governance of the Commons**

Why is the topic appropriate and timely?

The impacts of the SARS-CoV-2 pandemic continue to pose potential threats for global public health and economies which must restructure to make up for the reduction in growth and lost income experienced during the pandemic. Public finances remain under pressure and health systems have been compromised. We need to learn how to improve our strategic preparedness and response for future pandemics.

There are also urgent issues around vaccine inequity that disproportionately affected national response efforts in the Global South and hindered the ability of low-income countries to improve living standards. Insufficient knowledge transfer and capability-building slowed the adaptation of vaccines to meet local conditions. No consensus has yet emerged on how these inequities should have been addressed (e.g., container-factories versus strengthening regional innovation systems and capabilities in the Global South). New generation mRNA-based vaccines are rapidly emerging, but it is still uncertain whether, in the event of a new viral pandemic, vaccines can be manufactured, stored, and distributed at the scale and with the right geographic spread to address global vaccine needs, including those of middle and low-income countries.

Reference

Watson, O, Barnsley, G, Toor, J, Hogan, A, Winskill, P and Ghani, A (2022) Global impact of the first year of Covid19 vaccination: a mathematical modelling study. *The Lancet*, 22, September, 1293-2022.

**Conference Programme
11-12 April 2024
SOAS University of London**

Day 1: April 11, 2024

8.30 - 9.00 Registration Tea, Coffee and Biscuits

9.00 Welcome Address – Professor Joanna Newman, MBE, FRSA, Provost and Deputy Vice Chancellor Education, SOAS University of London

9.15 - 12.30 SESSION I: R&D, VACCINE INVENTION AND INNOVATION

[Refreshment Break – 10.45-11.00]

Session Theme

The main purpose of this session is to discuss the financing of the research and development of vaccines. It will cover public and business funding of R&D, links between the science base and industry (for the development and manufacture of vaccines) and the implications of different forms of financing for vaccine equity. The participants in this section are drawn from science, medical and social science backgrounds.

Chair: *Christine Oughton, SOAS University of London*

Speaker	Job Title, Organisation	Subject Area
<i>Jerome H. Kim</i>	<i>Director General, International Vaccine Institute, South Korea</i>	<i>Vaccine research and</i>
<i>William Lazonick</i>	<i>Emeritus Professor University of Massachusetts and President of AIRnet</i>	<i>Business and economics of innovation,</i>
<i>Margareth Ndomondo-Sigonda</i>	<i>Head of Health Programmes, Africa Union Development Agency-NEPAD</i>	<i>Public health, pharmaceutical manufacturing, medical</i>
<i>Maria Bottazzi</i>	<i>Professor, Co-Director & Associate Dean, Texas Children's Hospital Center for Vaccine Development; National School of Tropical Medicine, Baylor College of Medicine</i>	<i>Vaccine research; physician of infectious diseases</i>
<i>Padmashree Gehl Sampath</i>	<i>Chief Executive Officer of the African Pharmaceutical Technology Foundation, Special Adviser to African Development Bank, Chair on Industrial Development, University of Johannesburg, Research Fellow Harvard University.</i>	<i>Global health studies, technology development, trade, innovation, industrial performance and transformations</i>

12.30 - 13.30 Lunch and Networking, The Cloisters, Senate House, SOAS University of London

13.30 - 17.00 SESSION II: VACCINE NATIONALISM, VACCINE INEQUITY, PRODUCTION AND IPR
[Refreshment Break 15.00 - 15.15]

Session Theme

This session will explore financing of research and development, intellectual property rights, prices for, and access to new drugs, vaccines, and other medical technologies. The central question is to explore the role of intellectual property rights in shaping R&D, knowledge and technology transfer and the pricing and distribution of vaccines, including the adequacy of the June 2022 WTO patent waiver, voluntary patent waivers and the use of compulsory licensing.

Chair: *Öner Tulum, Executive Director of Research, AIRnet; Research Affiliate, SOAS University of London and Watson Institute, Brown University*

Speaker	Job Title, Organisation	Subject Area
<i>Julia Barnes-Weise</i>	<i>Executive Director, Global Healthcare Innovation Alliances Accelerator (GHIAA)</i>	<i>Intellectual property rights, pharma product licensing, global public health security</i>
<i>Phil Alvelda</i>	<i>CEO and Chairman of Brainworks Foundry, Inc</i>	<i>AI enhanced healthcare technologies and services</i>
<i>Duncan Matthews</i>	<i>Professor of IP Law, Queen Mary University of London</i>	<i>Intellectual property rights</i>
<i>Christine Oughton</i>	<i>Professor of Management Economics, SOAS University of London</i>	<i>Innovation diffusion, patents and social welfare</i>
<i>James P. Love</i>	<i>Director, Knowledge Ecology International</i>	<i>Financing R&D, IPR, prices and access to new drugs, vaccines, and other medical technologies</i>

Rooms available for media interviews 12.30 - 13.30 and 17.00 - 18.00

Day 2
April 12, 2024

9.15 - 12.30 SESSION III: BUILDING CAPABILITIES AND CATALYSING INNOVATION SYSTEMS, TECHNOLOGY TRANSFER AND VACCINE MANUFACTURING CAPABILITIES

[Refreshment Break – 10.45 - 11.00]

Theme of Session

The main purpose of this session is how to build capabilities to strengthen national and regional innovation systems around the world. It will explore the factors shaping knowledge and technology transfer, with a focus on transfer from high to middle and low-income economies, as well as the geographic spread of manufacturing capabilities. It will also assess the merits of different strategies, for example, container factories versus strengthening regional innovation systems in the Global South, and mechanisms to foster greater international cooperation.

Chair: *Margareth Ndomondo- Sigonda, Head of Health Programmes, Africa Union Development Agency-NEPAD*

Speaker	Job Title, Organisation	Subject Area
<i>Hsu Huang</i>	<i>Brown University</i>	<i>Social foundations of non-Western science: Making COVID vaccines in China and Russia</i>
<i>Rohit Malpani</i>	<i>Independent consultant, Former Director of Policy and Analysis, Médecins Sans Frontières and UNITAID Board Member</i>	<i>IP law related to medicines and public policy</i>
<i>Suerie Moon</i>	<i>Co-Director and Professor of Practice, Global Health Centre, Geneva Graduate Institute</i>	<i>Knowledge networks, innovation and access to medicines</i>
<i>Öner Tulum</i>	<i>Executive Director of Research, AIRnet and Research Affiliate, Brown University</i>	<i>Business and economics of vaccine innovation</i>
<i>Petro Terblanche</i>	<i>Managing Director, Afrigen Biologics and Vaccines</i>	<i>Environmental disease, epidemiology, technology transfer and innovation, mRNA vaccines</i>

12.30 - 13.30 Lunch and Networking, The Cloisters, Senate House, SOAS University of London

Rooms available for media interviews 12.30 - 13.30 and 17.00 - 18.00

13.30 - 17.00 SESSION IV: STRENGTHENING GLOBAL GOVERNANCE OF THE COMMONS

[Refreshment Break – 15.00 - 15.15]

Session Theme:

The session will explore the global governance of public health, research and knowledge transfer, including the role of global institutions such as the WHO, WTO and the UN. A central theme will be how we can manage the global governance of public health and vaccines efficiently and fairly. It will also draw conclusions on how we can monitor progress and what is needed to improve preparedness for future public health crises.


Chair: *Bill Lazonick, Emeritus Professor University of Massachusetts and President of AIRnet*

Speaker	Job Title, Organisation	Subject Area
<i>Andrés Cárdenas</i>	<i>Research Associate, AIRnet</i>	<i>Economics of vaccine innovation, perspectives from Cuba</i>
<i>Jorge Saavedra</i>	<i>Executive Director, AHF Global Public Health Institute University of Miami and Member of the Panel for a Global Public Health Convention and The Global Pandemic Policy Group</i>	<i>Infectious diseases and global public health policy for the 21st century</i>
<i>Damian Tobin</i>	<i>Lecturer in Internal Business, University of Cork</i>	<i>Patents, innovation and governance, history of innovation and business</i>
<i>Thomas Ferguson</i>	<i>Director of Research, Institute for New Economic Thinking</i>	<i>Political economy of vaccine innovation, competition & governance</i>
<i>Jayati Ghosh</i>	<i>Professor of Economics, University of Massachusetts Amherst and Member of the UN Secretary General's High-Level Advisory Board on Effective Multilateralism</i>	<i>Political economy of vaccine production</i>

17.00 Close of Conference

Rooms available for media interviews 12.30-13.30 and 17.00-18.00


SPEAKERS




Christine Oughton is Professor of Management Economics at SOAS University of London an elected Fellow of the Academy of Social Sciences. She received her PhD in Economics from the University of Cambridge. Before joining SOAS she held full Professorships at the University of Bolzano, Italy and Birkbeck, University of London. Previously she was Senior Lecturer and Director of the Research Centre for Industrial Strategy at the University of Birmingham. Christine's research focuses on innovation, convergence, environmental management, corporate governance, financial diversity, financial inclusion and growth. She was co-investigator on the ESRC Research Seminar Series, *Complexity Economics for Sustainability* that brought together, academics, practitioners and policy makers on environmental issues, and on two ESRC projects looking at financial systems, inclusion and growth. Christine has published widely on innovation, environmental sustainability, governance, financial diversity and competitiveness. Her most recent research on innovation explores: (i) the impact of patents on the diffusion of innovations (e.g., vaccines and electric vehicles) to protect common pool resources, such as public health and the environment, and (ii) the transfer of technology from high to low-income countries to promote convergence and growth. Between 2012-16 she was Head of the School of Finance and Management and served on the SOAS Board of Trustees. Christine currently sits on the Board of Directors of the Financial Inclusion Forum and the Academic Industry Research Network.




Jerome H. Kim, M.D., is the Director General of International Vaccine Institute (IVI) and an international expert on the development and evaluation of vaccines. Prior to IVI, he served as the Principal Deputy, US Military HIV Research Program and the Chief, Laboratory of Molecular Virology and Pathogenesis at the Walter Reed Army Institute of Research; and the US Army Program Manager for HIV vaccines. He led the Army's RV144 Phase III HIV vaccine trial that showed efficacy in the prevention of HIV-1. Dr. Kim is an Adjunct Professor, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, USA; Adjunct Professor, Graduate School of Public Health, Yonsei University, Republic of Korea; and an Honorary Professor, University of Rwanda. He was also named a Distinguished Visiting Professor, Seoul National University in 2022. He has authored over 350 publications. Dr. Kim is a graduate of the University of Hawaii with high honors in History and highest honors in Biology, received his M.D. from the Yale University School of Medicine, and trained in Internal Medicine and Infectious Diseases at Duke University Medical Center. Dr. Kim has received numerous awards: John Maher Award for Research Excellence, Uniformed Services University (2013); Department of the Army Research and Development Achievement Award for Technical Excellence (2013); Asia Pacific Vaccine Excellence Lifetime Achievement Award (2021); Medal of Honor for Civil Merit from the Government of the Republic of Korea (2022).



Margareth Ndomondo-Sigonda works for AUDA-NEPAD as Head of Health Program. She is responsible for providing technical lead and strategic oversight on health and pharmaceutical programs such as the African Medicines Regulatory Harmonization Initiative, the establishment of African Medicines Agency as a specialized agency of the African Union, and promotion of local production of pharmaceuticals in Africa. She currently leads the regulatory workstream of the AU Partnerships for African Vaccines Manufacturing Framework. She previously served as Chief Pharmacist and Registrar of Pharmacy Board of Tanzania (1998-2003) and as the first Director General of the Tanzania Food and Drugs Authority (2003-2010). She holds a PhD in Pharmacology from the University of the Witwatersrand, Johannesburg, South Africa.



William Lazonick, professor emeritus of economics at University of Massachusetts, is co-founder and president of the Academic-Industry Research Network. He has been an Open Society Fellow and is currently a Canadian Institute for Advanced Research Fellow. Over the past decade, the Institute for New Economic Thinking has funded a number of his research projects. He has professorial affiliations with SOAS University of London and Institut Mines-Télécom in Paris. Previously, Lazonick was assistant and associate professor of economics at Harvard University, professor of economics at Barnard College of Columbia University, and distinguished research professor at INSEAD in France. Lazonick earned his B.Com. at the University of Toronto, M.Sc. in Economics at London School of Economics, and Ph.D. in Economics at Harvard University. He holds honorary doctorates from Uppsala University and the University of Ljubljana. Lazonick's research focuses on the social conditions of innovation and economic development in advanced and emerging economies. His book *Sustainable Prosperity in the New Economy? Business Organization and High-Tech Employment in the United States* won the 2010 Schumpeter Prize. He has twice—in 1983 and 2010—had the award from Harvard Business School for best article of the year in *Business History Review*. He received the HBR McKinsey Award for outstanding article in *Harvard Business Review* in 2014 for “Profits Without Prosperity: Stock Buybacks Manipulate the Market and Leave Most Americans Worse Off.” In January 2020, Oxford University Press published his book, co-authored with Jang-Sup Shin, *Predatory Value Extraction: How the Looting of the Business Corporation Became the U.S. Norm and How Sustainable Prosperity Can Be Restored*. His latest book is *Investing in Innovation: Confronting Predatory Value Extraction in the US Corporation* (Cambridge UP, 2023).




Maria E. Bottazzi, PhD is Sr. Associate Dean of the National School of Tropical Medicine, Professor of Pediatrics, Molecular Virology & Microbiology, Division Chief of Pediatric Tropical Medicine and Co-director of Texas Children's Center for Vaccine Development at Baylor College of Medicine in Houston and Distinguished Professor in Biology at Baylor University in Waco. She is an internationally recognized tropical and emerging disease vaccinologist, global health advocate and co-creator of a patent-free, open science COVID-19 vaccine technology that led to the development of Corbevax in India and IndoVac in Indonesia, and with approximately 100 million doses delivered. She pioneers and leads the advancement of a robust infectious and tropical disease vaccine portfolio tackling diseases such as coronavirus, hookworm, schistosomiasis, and Chagas that affect disproportionately the world's poorest populations. She also has established innovative partnerships in Latin America, Middle East and Southeast Asia, making significant contributions to innovative educational & research programs, catalyze policies and disseminate science information to reach a diverse set of audiences. As global thought-leader she has received national and international highly regarded awards, has more than 230 scientific papers and participated in more than 250 conferences worldwide. She is Member of the National Academy of Science of Honduras and Emerging Leader in Health and Medicine of the National Academy of Medicine in the US. Dr. Bottazzi is a Fellow of the American Society of Tropical Medicine and Hygiene (ASTMH), the Executive Leadership in Academic Medicine (ELAM), the Leshner Leadership Institute for Public Engagement and Sr. Fellow of the American Leadership Forum (ALF). *Forbes LATAM* in 2020 and 2021 selected Dr. Bottazzi as one of 100 Most Powerful Women in Central America. Dr. Bottazzi has served in several National Academies Ad-hoc Committees and serves as Co-chair of the Vaccines and Therapeutics Taskforce of the Lancet Commission on COVID-19. In 2022, alongside Dr. Peter Hotez, she was nominated by Congresswoman Lizzie Fletcher of Texas for the Nobel Peace Prize. Dr. Bottazzi obtained her bachelor's degree in microbiology and clinical chemistry from the National Autonomous University of Honduras and a doctorate in Molecular Immunology and Experimental Pathology from the University of Florida. Her post-doctoral training in Cellular Biology was done at University of Miami and Pennsylvania. She worked at George Washington University prior to relocating to Texas.



Padmashree Gehl Sampath is currently the Chief Executive Officer of the African Pharmaceutical Technology Foundation, and a Senior Advisor to the President of the African Development Bank. Until recently, she was a Fellow at the Berkman Klein Center, Harvard University and a Director of the Global Access in Action Program at the Center. She is an Honorary Professor, University of Rwanda and a Visiting Professor at the University of Johannesburg. She also leads a large international team examining the politics of vaccine production in Africa, as part of the Programme on Accelerating Vaccine Production in Africa: A Centres of Excellence Initiative. She is also a Professorial Fellow at the United Nations University-MERIT.



Julia Barnes-Weise is the founder and Executive Director of the Global Healthcare Innovation Alliance Accelerator (GHIAA), a non-profit organization that develops, promotes and consults on the use of tools and best practices to achieve equitable access through global health alliance formation. In this capacity she has also been a senior consultant to CEPI for over seven years. She trained as a lawyer, and is a global health policy consultant, business development executive, entrepreneur and Certified Licensing Professional. Barnes-Weise formerly had a faculty appointment in the Duke Sanford School of Public Policy and was previously a Director of Business Development at Glaxo Wellcome (now GSK). She has decades of experience negotiating IP licenses & alliance agreements and advising companies and institutions on partnering strategies. Her educational background includes a Juris Doctor degree from the University of North Carolina, a year at the Notre Dame London Law Centre studying international trade law, a BA from Ohio Wesleyan University, and an executive program at Duke University's Fuqua Business School in International Marketing Leadership. She is a member and recent board member of the Licensing Executives Society and a former board member of the Medical University of South Carolina Foundation for Research and Development. She has also served on several task forces and published articles on topics related to global public health security and equitable access to medical products.



Phillip Alvelda is the CEO and Chairman of Brainworks Foundry, Inc., a U.S. based developer of AI-enhanced healthcare technologies and services. Prior to Brainworks, Dr. Alvelda was a Program Manager at the Defense Advanced Research Projects Agency Biological Technologies Office where he developed and ran national scale R&D programs and technologies at the intersection of engineering and biology. Prior to DARPA, Dr. Alvelda was the founding CEO of MobiTV, which launched the world's first live television service over mobile networks, for which he was awarded an Emmy by the Academy of Motion Pictures, selected by Fast Company as the US's 15th most influential high-tech entrepreneur, and has received numerous other industry awards for innovation and market leadership. He is a regular invited speaker at science, technology, and education industry events, including the World Economic Forum where he was chosen as a "Technology Pioneer" in 2007. Prior to MobiTV, Dr. Alvelda founded The MicroDisplay Corporation, a manufacturer of miniature displays for low-cost HDTVs and VR headsets. Prior to MicroDisplay, Dr. Alvelda was a developer of spacecraft hardware and new neural computing architectures at NASA's Jet Propulsion Laboratory where he designed and built sensors that flew on the Space Shuttle as well as the Galileo and Magellan interplanetary spacecraft. Dr. Alvelda holds over 30 patents and patents-pending on a wide range of technologies, a technical Emmy Award, a Bachelor's degree in Physics from Cornell University, and Masters and PhD degrees in Computer Science and Electrical Engineering from MIT.



Duncan Matthews is Director of the Queen Mary Intellectual Property Research Institute and a member of the Centre for Commercial Law Studies. He has held academic positions as a lecturer in law at the University of Warwick and as a research fellow at the ESRC Centre for the Study of Globalisation and Regionalisation, also at the University of Warwick. He has worked as a researcher at a policy think-tank (the National Institute for Economic and Social Research, London) and as an EU lobbyist.

He has acted as an advisor to: Directorate General Trade of the European Commission; the ECAP II EC-ASEAN Intellectual Property Rights Co-operation Programme; the American Association for the Advancement of Science; the United Nations Development Programme; the European Parliament Committee on International Trade; the European Patent Office; the UK Strategic Advisory Board for Intellectual Property Policy; and the UK Intellectual Property Office Expert Advisory Group on Trade and Development. He is the author of *Globalising Intellectual Property Rights, Intellectual Property, Human Rights and Development* and co-editor of the *Research Handbook on Intellectual Property and the Life Sciences*.



James P. Love is Director of Knowledge Ecology International. His training is in economics and finance, and his work focuses on the production, management and access to knowledge resources, as well as aspects of competition policy. The current focus is on the financing of research and development, intellectual property rights, prices for and access to new drugs, vaccines and other medical technologies, as well as related topics for other knowledge goods, including data, software, other

information protected by copyright or related rights, and proposals to expand the production of knowledge as a public good. James Love holds a Masters of Public Administration from Harvard University's Kennedy School of Government and a Masters in Public Affairs from Princeton's Woodrow Wilson School of Public and International Affairs. He advises UN agencies, national governments, international and regional intergovernmental organizations and public health NGOs, and is the author of a number of articles and monographs on innovation and intellectual property rights. Knowledge Ecology International was created in 2006 as a separate entity to carry out work earlier done through the Center for Study of Responsive Law and Essential Information, where Love was employed from 1990 to 2006. Prior to that, he was Senior Economist for the Frank Russell Company, a lecturer at Rutgers University, and a researcher on international finance at Princeton University. In 2006, Knowledge Ecology International received a MacArthur Award for Creative and Effective Institutions. In 2007, Love received the Public Knowledge IP3 award. In 2013, Love received the EFF Pioneer Award, to recognize leaders who extend freedom and innovation in the realm of information technology. In 2015, he received, with his wife Manon Ress, the Joe A. Callaway Award for Civic Courage.



Hsu Huang is a PhD candidate in sociology at Brown University. He obtained his bachelor's and master's degrees at Renmin University of China, European University at Saint Petersburg, and King's College London, and was a visiting fellow at Davis Center for Russian and Eurasian Studies at Harvard University. He studies scientists, scientific knowledge, organizations, and macro-level socio-political change in a comparative-historical perspective, drawing on cases from 1) COVID- 19 vaccine development in China and Russia; 2) purges and rehabilitations of Soviet sociologists in 1958-1987; 3) "culling" of middle management through the East Asian developmental state, military coups in Latin American, the welfare state in the North Atlantic, and the political persecutions in Soviet Union and China.



Öner Tulum is Executive Director of Research at the Academic-Industry Research Network, and a research affiliate of the William R. Rhodes Center for International Economics and Finance at the Watson Institute of Brown University. His current research on the pharmaceutical industry is being funded by grants from the Institute for New Economic Thinking and the Canadian Institute for Advanced Research. In 2019, Tulum completed a post-doctoral fellowship at SOAS University of London, funded by the Gatsby Foundation, after completing his PhD at the University of Ljubljana in 2018, with funding from the European Union Horizon 2020 Research and Innovation Programme as part of the project, Innovation-fuelled Sustainable, Inclusive Growth in Europe. Tulum's research on the tension between innovation and financialization draws upon, and has helped develop, "the theory of innovative enterprise". Results of his research have appeared in *Competition and Change*, *Cambridge Elements in Reinventing Capitalism*, *The New York Times*, the *International Journal of Political Economy*, *Accounting Forum*, and *Research Policy*. Previously, Tulum was a visiting scholar at the University of Massachusetts Amherst, and a Marie Curie Research Fellow at the National University of Ireland Galway. Tulum received an MBA and M.A. in Regional Economic and Social Development from the University of Massachusetts.



Rohit Malpani is an independent consultant, based in Paris, working on: the ethics and governance of artificial intelligence in health, antimicrobial resistance, and access to medicines. Previously, he was the Director of Policy for the Medecins Sans Frontieres Access Campaign, a Special Advisor at Oxfam, and an intellectual property attorney for the law firm Wilson, Sonsini in Palo Alto, California. He has a Doctorate of Jurisprudence from the New York University School of Law.



Petro Terblanche is Chief Executive Officer of Afrigen Biologics, a research, development and manufacturing entity, which hosts the World Health Organization's Global mRNA Technology Development and Transfer Hub. She has played a key part in the design and implementation of South Africa's biotechnology strategy, spending much of her career with the South African Medical Research Council and the Council for Scientific and Industrial Research. Professor Terblanche holds several Board positions in South Africa and was recently acknowledged as one of the legends of science by the Academy of Sciences South Africa.



Suerie Moon is Co-Director at the Global Health Centre and Professor of Practice for the Interdisciplinary Programmes and International Relations/Political at the Science Graduate Institute of International and Development Studies, Geneva, which she joined in 2016. Before this, she was Lecturer on Global Health at the Harvard T.H. Chan School of Public Health. Suerie is also former Study Director of the Harvard-LSHTM Independent Panel on the Global Response to Ebola and co-directed the Project on Innovation and Access to Technologies for Sustainable Development at the Kennedy School of Government. She received a BA in history from Yale, an MPA in international relations from Princeton, and PhD in public policy from the Harvard Kennedy School of Government.



Jorge Saavedra MD, MPH, MSc is Executive Director of the AHF Global Public Health Institute at the University of Miami. Elected by the Mexican Senate as Member of the Consultative Council of the National Human Rights Commission. Member of the Panel for a Global Public Health Convention and The Global Pandemic Policy. Former Panelist of The Independent Panel to Evaluate the Global Response to Ebola convened the London School of Hygiene and Tropical Medicine. From 2003-2009 Director General of the National AIDS Program of Mexico.

Founding Director of Mexico City Clinica Condesa, the largest HIV Clinic in Latin America. MD degree from the National University of Mexico (UNAM); MPH. and MSc degrees at Harvard University. Former Global Fund Board Member Representing Latin America & Caribbean and former member of the Developing Country NGO constituency. Recent relevant publications: “MPOX vaccines needed in Mexico”, The Lancet Regional Health Americas. March 6, 2023. “A Global Public Health Convention for the XXI Century”, The Lancet Public Health, May 5, 2021.



Damian Tobin is Lecturer in International Business at Cork University Business School. Dr. Tobin’s research focuses on a number of areas including economic development (state-owned banks, currency internationalization and financial inclusion), business history, common pool resources (climate and public health) and technology diffusion. His research has been published in such journals as Research Policy, Cambridge Journal of Economics, New Political Economy, Journal of International Development, Business History, World Development, and Corporate

Governance: An International Review, as well as in broader media outlets. Dr. Tobin has experience in providing economic policy briefings for international corporations, governments, social think-tanks, and advisory firms. Dr. Tobin is a graduate of the University of Limerick (MBS Economics & BA Public Administration) and has a Ph.D. in Finance and Management from the University of London. His thesis looked at corporate restructuring, governance reform, and the international listing of China's leading state-owned enterprises. He has been a visiting researcher at universities in Hong Kong and Italy.



Andrés Cárdenas O’Farrill Andrés Cárdenas O’Farrill is a senior research associate of the Academic–Industry Research Network. He earned an economics degree from the University of Havana and began his career as an economist at the Cuban Ministry of Economy, specializing in the energy sector. Later, he worked as a research consultant in renewable energy for GTS (Gesellschaft für ökologische Technologie und Systemanalyse e.V.), a German academic association affiliated with the European Federation of Biotechnology. Cárdenas O’Farrill has provided consultancy services to European institutions such as the

European Parliament's STOA Panel on the feasibility of establishing a permanent European public biomedical research infrastructure. He has also collaborated with the US-based institution Democracy Collaborative in analyzing a public option in the pharmaceutical industry. Additionally, he holds a master's degree in economics from the University of Leipzig and a PhD from the University of Bremen, both in Germany. In 2021, Routledge published his book, Cooperation Networks and Economic Development: Cuba’s High-Tech Potential.



Thomas Ferguson is the Research Director at the Institute for New Economic Thinking. He is Professor Emeritus at the University of Massachusetts, Boston and Senior Fellow at Better Markets. He received his Ph.D. from Princeton University and taught formerly at MIT and the University of Texas, Austin. He is the author or coauthor of several books, including *Golden Rule* (1995) and *Right Turn* (1986). His articles have appeared in many scholarly journals, including the *Quarterly Journal of Economics*, *International Organization*, *International Studies Quarterly*, and the *Journal of Economic History*. He is a member of the editorial board of the *International Journal of Political Economy* and a longtime Contributing Editor at *The Nation*.



Jayati Ghosh taught economics at Jawaharlal Nehru University, New Delhi for nearly 35 years, and since January 2021 she has been Professor of Economics at the University of Massachusetts Amherst, USA. She has authored and/or edited over 20 books and 200 scholarly articles and received several prizes, including the 2015 Adisheshaiah Award for distinguished contributions to the social sciences in India; the International Labour Organisation's Decent Work Research Prize for 2011; and the NordSud Prize for Social Sciences 2010, Italy. She has advised governments in India and other countries, including as Chairperson of the Andhra Pradesh Commission on Farmers' Welfare in 2004, and Member of the National Knowledge Commission of India (2005-09). She was the Executive Secretary of International Development Economics Associates, an international network of heterodox development economists, from 2002 to 2021. In 2023, she was awarded the John Kenneth Galbraith award by the Agricultural and Applied Economics Association. She has consulted for international organizations including ILO, UNDP, UNCTAD, UN-DESA, UNRISD and UN Women and is member of several international boards and commissions, including the UN High-Level Advisory Board on Economic and Social Affairs, the Commission on Global Economic Transformation of INET, the International Commission for the Reform of International Corporate Taxation. In 2021 she was appointed to the WHO Council on the Economics of Health for All, chaired by Mariana Mazzucato. In March 2022, she was appointed to the UN Secretary General's High-Level Advisory Board on Effective Multilateralism, mandated to provide a vision for international cooperation to deal with current and future challenges. Ghosh writes regularly for newspapers, journals and blogs.
